| ID | 1199 |
| Name of the vaccine | SC602 |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | NA |
| Description of the vaccine | Shigella flexneri 2a strain SC602. |
| Name of the manufacturer | Institut Pasteur |
| Name of the manufacturing country | NA |
| Year of manufacture | NA |
| Clinical Phase status | Clinical |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Lyophilized |
| Dosage | Single dose. |
| Mechanism of action | IgA ASC response and a threefold or greater rise in serum IgA antibody, urinary sIgA responses in addition to IgG ASC and IgG serum responses. |
| Route of administration | Ingestion |
| Indications | Protection against fever and severe shigellosis. |
| Export | NA |
| Approval | Conducted under Food and Drug Administration investigational new drug application. |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Abdominal cramps, nausea, emesis, tenesmus, gas, headache, myalgia, arthralgia, loss of appetite and fatigue. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 10377124 |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=259&keywords= |
| Other name | NA |
| Additional Links | NA
|